The involvement of molecular markers such as IKZF1, CDKN2A, and antigen receptor gene deletions in IGH or TRG2 can distinguish between de novo BCR‐ABL1+ AML from myeloid blast crisis of CML.1, 2. This evidence concerns the gene CDKN2A and chronic myelogenous leukemia, BCR-ABL1 positive.